BioCryst Pharmaceuticals Inc
F:BO1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioCryst Pharmaceuticals Inc
F:BO1
|
US |
|
UiPath Inc
NYSE:PATH
|
US |
|
A
|
Aluminum Corporation of China Ltd
XMUN:AOC
|
CN |
|
Viel et Compagnie SA
F:VIC
|
FR |
|
Itway SpA
MIL:ITW
|
IT |
|
Melia Hotels International SA
F:MEL
|
ES |
|
Multitude AG
XETRA:MULT
|
CH |
|
Laurentian Bank of Canada
TSX:LB
|
CA |
|
Schindler Holding AG
F:SHR
|
CH |
Intrinsic Value
Is BO1 undervalued or overvalued?
See the intrinsic value estimate for 
BioCryst Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
BO1 looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with BO1’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What BioCryst Pharmaceuticals Does
BioCryst Pharmaceuticals is a biotechnology company that makes medicines for rare diseases, with a strong focus on hereditary angioedema, a genetic condition that causes repeated swelling attacks. Its main marketed product is Orladeyo, an oral preventive treatment that patients take long term. The company also develops other drug candidates for rare immune and inflammatory disorders, but its business is built around selling specialty medicines rather than broad consumer health products.
- Headquarters
- United States of America US
- Employees
- 435
- IPO date
- Mar 4, 1994
Revenue & Expenses Breakdown
BioCryst Pharmaceuticals Inc
Earnings Waterfall
BioCryst Pharmaceuticals Inc
The intrinsic value for BioCryst Pharmaceuticals Inc (BO1) under the Base Case is hidden EUR.
Compared with the current market price of 6.756 EUR, the stock appears hidden.